Unknown PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT03014102

Recombinant Human Thrombopoietin for Mobilization of Peripheral Blood Progenitor Cells for Autologous Transplantation

Sponsor: Hongnan Mo

Conditions Hematopoietic Stem Cell Mobilization Hematopoietic Stem Cell Transplantation Thrombocytopoietin

Interventions Recombinant Human Thrombopoietin

Updated 8 times since 2017 Last updated: Dec 5, 2019 Started: Jun 30, 2016 Primary completion: Sep 30, 2020 Completion: Sep 30, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03014102, this PHASE1/PHASE2 trial focuses on Hematopoietic Stem Cell Mobilization and Hematopoietic Stem Cell Transplantation and remains ongoing. Sponsored by Hongnan Mo, it has been updated 8 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Mar 2022 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2

Status: Recruiting → Unknown Status
Jan 2021 — Mar 2022 [monthly]

Recruiting PHASE1_PHASE2
Jan 2020 — Jan 2021 [monthly]

Recruiting PHASE1_PHASE2

▶ Show 3 earlier versions

Sep 2019 — Jan 2020 [monthly]

Recruiting PHASE1_PHASE2
Jun 2018 — Sep 2019 [monthly]

Recruiting PHASE1_PHASE2
Feb 2017 — Jun 2018 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Jun 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hongnan Mo

Data source: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China